Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25


Targeting mRNA processing as an anticancer strategy.

Desterro J, Bak-Gordon P, Carmo-Fonseca M.

Nat Rev Drug Discov. 2019 Sep 25. doi: 10.1038/s41573-019-0042-3. [Epub ahead of print] Review.


Essential thrombocythaemia treated with recombinant interferon: 'real world' United Kingdom referral centre experience.

Desterro J, McLornan DP, Curto Garcia N, O'Sullivan J, Alimam S, Keohane C, Woodley C, Francis Y, Kordasti S, Radia DH, Harrison CN.

Br J Haematol. 2019 Aug;186(4):561-564. doi: 10.1111/bjh.15968. Epub 2019 May 15.


Age-adjusted international prognostic index is a predictor of survival in gastric diffuse B-cell non-Hodgkin lymphoma patients.

Delamain MT, da Silva MG, Miranda EC, Desterro J, Luminari S, Fedina A, Merli F, Chiattone CS, Pagnano KB, Federico M, de Souza CA.

Rev Bras Hematol Hemoter. 2016 Jul-Sep;38(3):247-51. doi: 10.1016/j.bjhh.2016.04.010. Epub 2016 May 18.


Pervasive transcription read-through promotes aberrant expression of oncogenes and RNA chimeras in renal carcinoma.

Grosso AR, Leite AP, Carvalho S, Matos MR, Martins FB, Vítor AC, Desterro JM, Carmo-Fonseca M, de Almeida SF.

Elife. 2015 Nov 17;4. pii: e09214. doi: 10.7554/eLife.09214.


SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint.

Carvalho S, Vítor AC, Sridhara SC, Martins FB, Raposo AC, Desterro JM, Ferreira J, de Almeida SF.

Elife. 2014 May 6;3:e02482. doi: 10.7554/eLife.02482.


Splicing factors SF1 and U2AF associate in extraspliceosomal complexes.

Rino J, Desterro JM, Pacheco TR, Gadella TW Jr, Carmo-Fonseca M.

Mol Cell Biol. 2008 May;28(9):3045-57. doi: 10.1128/MCB.02015-07. Epub 2008 Feb 19.


A stochastic view of spliceosome assembly and recycling in the nucleus.

Rino J, Carvalho T, Braga J, Desterro JM, Lührmann R, Carmo-Fonseca M.

PLoS Comput Biol. 2007 Oct;3(10):2019-31. Epub 2007 Sep 5.


In vivo requirement of the small subunit of U2AF for recognition of a weak 3' splice site.

Pacheco TR, Coelho MB, Desterro JM, Mollet I, Carmo-Fonseca M.

Mol Cell Biol. 2006 Nov;26(21):8183-90. Epub 2006 Aug 28.


SUMO-1 modification alters ADAR1 editing activity.

Desterro JM, Keegan LP, Jaffray E, Hay RT, O'Connell MA, Carmo-Fonseca M.

Mol Biol Cell. 2005 Nov;16(11):5115-26. Epub 2005 Aug 24.


SUMO-1 modification of human transcription factor (TF) IID complex subunits: inhibition of TFIID promoter-binding activity through SUMO-1 modification of hsTAF5.

Boyer-Guittaut M, Birsoy K, Potel C, Elliott G, Jaffray E, Desterro JM, Hay RT, Oelgeschläger T.

J Biol Chem. 2005 Mar 18;280(11):9937-45. Epub 2005 Jan 6.


Dynamic association of RNA-editing enzymes with the nucleolus.

Desterro JM, Keegan LP, Lafarga M, Berciano MT, O'Connell M, Carmo-Fonseca M.

J Cell Sci. 2003 May 1;116(Pt 9):1805-18.


P14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2.

Xirodimas DP, Chisholm J, Desterro JM, Lane DP, Hay RT.

FEBS Lett. 2002 Sep 25;528(1-3):207-11.


Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9.

Tatham MH, Jaffray E, Vaughan OA, Desterro JM, Botting CH, Naismith JH, Hay RT.

J Biol Chem. 2001 Sep 21;276(38):35368-74. Epub 2001 Jul 12.


Common properties of nuclear body protein SP100 and TIF1alpha chromatin factor: role of SUMO modification.

Seeler JS, Marchio A, Losson R, Desterro JM, Hay RT, Chambon P, Dejean A.

Mol Cell Biol. 2001 May;21(10):3314-24.


Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation.

Rodriguez MS, Desterro JM, Lain S, Lane DP, Hay RT.

Mol Cell Biol. 2000 Nov;20(22):8458-67.


Regulation of transcription factors by protein degradation.

Desterro JM, Rodriguez MS, Hay RT.

Cell Mol Life Sci. 2000 Aug;57(8-9):1207-19. Review.


An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.

Midgley CA, Desterro JM, Saville MK, Howard S, Sparks A, Hay RT, Lane DP.

Oncogene. 2000 May 4;19(19):2312-23.


Control of NF-kappa B transcriptional activation by signal induced proteolysis of I kappa B alpha.

Hay RT, Vuillard L, Desterro JM, Rodriguez MS.

Philos Trans R Soc Lond B Biol Sci. 1999 Sep 29;354(1389):1601-9. Review.


SUMO-1 modification activates the transcriptional response of p53.

Rodriguez MS, Desterro JM, Lain S, Midgley CA, Lane DP, Hay RT.

EMBO J. 1999 Nov 15;18(22):6455-61.


Identification of the enzyme required for activation of the small ubiquitin-like protein SUMO-1.

Desterro JM, Rodriguez MS, Kemp GD, Hay RT.

J Biol Chem. 1999 Apr 9;274(15):10618-24.


SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation.

Duprez E, Saurin AJ, Desterro JM, Lallemand-Breitenbach V, Howe K, Boddy MN, Solomon E, de Thé H, Hay RT, Freemont PS.

J Cell Sci. 1999 Feb;112 ( Pt 3):381-93.


SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation.

Desterro JM, Rodriguez MS, Hay RT.

Mol Cell. 1998 Aug;2(2):233-9.


Ubch9 conjugates SUMO but not ubiquitin.

Desterro JM, Thomson J, Hay RT.

FEBS Lett. 1997 Nov 17;417(3):297-300.

Supplemental Content

Loading ...
Support Center